New partnership to develop treatment for peanut allergies

Date 04.18.2018 | Category: News
| Comments:

Vote:
CHR Hansen peanut IDM Apr18.jxr

Prota Therapeutics is pioneering a new form of oral immunotherapy treatment that combines Chr. Hansen’s specifically formulated LGG4 probiotic strain, Lactobacillus rhamnosus, with targeted doses of proprietary formulations of peanut protein. The treatment is designed to reprogram the immune system’s response to peanuts and eventually develop tolerance.


Building upon earlier trials conducted at the Murdoch Children’s Research Institute, Prota Therapeutics is progressing towards a large-scale Phase III clinical trial, under a US Investigational New Drug Application (IND). The aim is to commercialize a medicinal product using a new pharmaceutical grade therapeutic dosage form for treating peanut allergy, and to explore indications for treating other food allergies.


Says Dr. Suzanne Lipe, CEO at Prota Therapeutics: "An effective therapy to treat peanut allergies is now a realistic target. Chr. Hansen is the ideal partner for us in this next step, both as the owner of one of the key components in the therapeutic product – LGG – and as a leading expert in microbial solutions. Chr. Hansen has demonstrated the capability to deliver a pharmaceutical quality product that can be regulated as a biological therapeutic product. Together with our proprietary peanut protein formulation, we aim to progress this through to commercialization of a treatment for peanut allergies.”


Having produced LGG for more than 10 years before fully acquiring LGG from Valio in 2016, this new partnership is an example of how Chr. Hansen’s focus on industry leading product quality and clinical documentation can expand the potential of the LGG probiotic strain into a new breakthrough area.


Says Christian Barker, Executive Vice President, Health & Nutrition at Chr. Hansen: “Chr. Hansen has the ability to maximize the value of a probiotic strain through our deep experience in microbial process development and formulation, our focus on quality, and our global reach. The partnership with Prota Therapeutics is part of our strategy to become the partner of choice for companies wanting to develop new generations of therapeutic microbes.”


Lactobacillus rhamnosus is the best documented probiotic strain in the world. It has been used in food, dietary supplements and infant nutrition since 1990 and has shown beneficial effects on the gastrointestinal and immune system. It is supported by more than 300 clinical studies and 1,200 scientific publications. For more visit chr-hansen.com



Source: CHR Hansen
Author: COX
Load more news » Loading news